SYRE
Price
$14.46
Change
+$0.33 (+2.34%)
Updated
Apr 28, 02:42 PM (EDT)
Capitalization
851.69M
10 days until earnings call
ZURA
Price
$1.35
Change
-$0.02 (-1.46%)
Updated
Apr 28, 02:52 PM (EDT)
Capitalization
93.67M
Ad is loading...

SYRE vs ZURA

Header iconSYRE vs ZURA Comparison
Open Charts SYRE vs ZURABanner chart's image
Spyre Therapeutics
Price$14.46
Change+$0.33 (+2.34%)
Volume$700
Capitalization851.69M
Zura Bio
Price$1.35
Change-$0.02 (-1.46%)
Volume$105
Capitalization93.67M
SYRE vs ZURA Comparison Chart
Loading...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZURA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
SYRE vs. ZURA commentary
Apr 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SYRE is a StrongBuy and ZURA is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 28, 2025
Stock price -- (SYRE: $14.13 vs. ZURA: $1.37)
Brand notoriety: SYRE and ZURA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SYRE: 52% vs. ZURA: 50%
Market capitalization -- SYRE: $851.69M vs. ZURA: $93.67M
SYRE [@Biotechnology] is valued at $851.69M. ZURA’s [@Biotechnology] market capitalization is $93.67M. The market cap for tickers in the [@Biotechnology] industry ranges from $272.78B to $0. The average market capitalization across the [@Biotechnology] industry is $2.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SYRE’s FA Score shows that 0 FA rating(s) are green whileZURA’s FA Score has 0 green FA rating(s).

  • SYRE’s FA Score: 0 green, 5 red.
  • ZURA’s FA Score: 0 green, 5 red.
According to our system of comparison, ZURA is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SYRE’s TA Score shows that 4 TA indicator(s) are bullish while ZURA’s TA Score has 5 bullish TA indicator(s).

  • SYRE’s TA Score: 4 bullish, 4 bearish.
  • ZURA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both SYRE and ZURA are a good buy in the short-term.

Price Growth

SYRE (@Biotechnology) experienced а +11.52% price change this week, while ZURA (@Biotechnology) price change was +11.38% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +10.74%. For the same industry, the average monthly price growth was +0.71%, and the average quarterly price growth was -9.55%.

Reported Earning Dates

SYRE is expected to report earnings on Jul 31, 2025.

ZURA is expected to report earnings on Mar 25, 2025.

Industries' Descriptions

@Biotechnology (+10.74% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($852M) has a higher market cap than ZURA($93.7M). ZURA has higher P/E ratio than SYRE: ZURA (7.96) vs SYRE (1.72). SYRE YTD gains are higher at: -39.304 vs. ZURA (-45.200). ZURA has higher annual earnings (EBITDA): -50.28M vs. SYRE (-208.57M). SYRE has more cash in the bank: 603M vs. ZURA (188M). SYRE (0) and ZURA (0) have equivalent revenues.
SYREZURASYRE / ZURA
Capitalization852M93.7M909%
EBITDA-208.57M-50.28M415%
Gain YTD-39.304-45.20087%
P/E Ratio1.727.9622%
Revenue00-
Total Cash603M188M321%
Total Debt0N/A-
FUNDAMENTALS RATINGS
SYRE: Fundamental Ratings
SYRE
OUTLOOK RATING
1..100
15
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
95
PRICE GROWTH RATING
1..100
92
P/E GROWTH RATING
1..100
77
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
SYREZURA
RSI
ODDS (%)
Bullish Trend 4 days ago
82%
N/A
Stochastic
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
52%
Momentum
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
52%
MACD
ODDS (%)
Bullish Trend 4 days ago
86%
Bullish Trend 4 days ago
48%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
44%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 4 days ago
71%
Advances
ODDS (%)
Bullish Trend 5 days ago
85%
Bullish Trend 7 days ago
79%
Declines
ODDS (%)
Bearish Trend 13 days ago
90%
Bearish Trend 25 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
33%
Aroon
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 5 days ago
76%
View a ticker or compare two or three
Ad is loading...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZURA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ACETX10.03N/A
N/A
Invesco Equity and Income Y
PCPAX20.48-0.02
-0.10%
PACE Large Co Value Equity A
SSDAX28.65-0.05
-0.17%
DWS Small Cap Growth A
DGSCX38.81-0.41
-1.05%
Virtus KAR Global Small-Cap Inst
PXSGX28.24-0.53
-1.84%
Virtus KAR Small-Cap Growth I

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with CGON. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then CGON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
-5.36%
CGON - SYRE
53%
Loosely correlated
+3.95%
APGE - SYRE
52%
Loosely correlated
-0.54%
PRME - SYRE
50%
Loosely correlated
-3.43%
ACLX - SYRE
50%
Loosely correlated
-0.41%
IMNM - SYRE
49%
Loosely correlated
-1.41%
More

ZURA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZURA has been loosely correlated with CGON. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if ZURA jumps, then CGON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZURA
1D Price
Change %
ZURA100%
-4.86%
CGON - ZURA
40%
Loosely correlated
+3.95%
SYRE - ZURA
40%
Loosely correlated
-5.36%
OCUL - ZURA
38%
Loosely correlated
-2.41%
PRME - ZURA
37%
Loosely correlated
-3.43%
CGEM - ZURA
36%
Loosely correlated
N/A
More